

Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy

Chalirmporn Atasilp¹, Pichai Chansriwong², Ekapob Sirachainan², Thanyanan Reungwetwattana², Suwannee Sirilertrakul², Monpat Chamnanphon³, Apichaya Puangpetch^{4,5} & Chonlaphat Sukasem^{4,5*}

¹Faculty of Medical Technology, Rangsit University, Pathum Thani, Thailand

²Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

³Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁴Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

⁵Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debaratana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand

***Correspondence to: Chonlaphat Sukasem, B.Pharm., Ph. D**

Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 10400, Email: chonlaphat.suk@mahidol.ac.th

Telephone: (+66)-2-200-4330

Fax: (+66)-2-200-4332

Characteristics	Number of patients (%)
Age (years), range	62 (53-71)
Gender	
Male	78 (60.0)
Female	54 (40.0)
Site of disease	
Rectum	55 (41.7)
Sigmoid	38 (28.8)
Right side	14 (10.6)
Rectosigmoid	12 (9.1)
Left side	8 (6.1)
Transverse	5 (3.8)
Sites of metastases	
Liver	68 (42.8)
Lung	38 (23.9)
Others	4 (2.5)
No metastases	49 (30.8)
Histopathology type	
Well differentiated	41 (31.1)
Moderately differentiated	85 (64.4)
Poorly differentiated	6 (4.6)
Treatment regimen	
No irinotecan-based chemotherapy	66 (50.0)
Irinotecan-based chemotherapy	66 (50.0)

Supplement Table S1. Clinical characteristics of 132 colorectal cancer patients